Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases

Details for Australian Patent Application No. 2005288522 (hide)

Owner Quark Pharmaceuticals, Inc.

Inventors Feinstein, Elena; Zurr, Daniel; Ehrlich, Shai

Agent Cullens

Pub. Number AU-B-2005288522

PCT Pub. Number WO2006/035434

Priority 60/658,196 02.03.05 US; 60/703,020 26.07.05 US; 60/613,991 28.09.04 US

Filing date 27 September 2005

Wipo publication date 6 April 2006

Acceptance publication date 28 June 2012

International Classifications

C07H 21/00 Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

A61K 31/70 - Carbohydrates

Event Publications

5 April 2007 PCT application entered the National Phase

  PCT publication WO2006/035434 Priority application(s): WO2006/035434

23 August 2007 Change of Name(s) of Applicant(s), Section 104

  Quark Biotech, Inc. The name of the applicant has been changed to Quark Pharmaceuticals, Inc.

28 June 2012 Application Accepted

  Published as AU-B-2005288522

1 November 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005288527-Recombinant human T2 RNase and uses thereof

2005288521-Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride